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Background:  The  introduction  of  levodopa  in  clinical  practice  represents  a hallmark  in the treatment  of
the neurodegenerative  disease,  Parkinson’s  Disease.  However,  levodopa  induced  motor  complications,
namely  dyskinesias  and  motor  ﬂuctuations,  develop  in  the  majority  of  Parkinson’s  Disease  patients.
Objective:  to identify  which  Parkinson’s  Disease’s,  patient’s  and  therapeutics’  initial  features  are  more
associated  with  dyskinesias  or motor  ﬂuctuations  development.
Methods:  Patients  with diagnosed  Parkinson’s  Disease  attending  neurology  outpatient  clinic at  Centro
Hospitalar  São  João  were  selected.  For  this  observational  study,  data  was  retrospectively  collected  from
patient’s  clinical  records.  A survival  analysis  model  with  univariate  and  multivariate  regression  analysis
was  used.
Results:  87  patients  with  a  mean  of  72  ±  9.7  years  were  included.  After  a median  follow-up  of 6  (range
1–17)  years,  35.6%  patients  developed  dyskinesias;  and  with  a  median  of  5 (range  1–16)  years,  32.2%
developed  motor  ﬂuctuations.  After  multivariate  analysis,  the  akinesia/rigidity  subtype  was  found  to  have
a  higher  risk  of  dyskinesias  and  motor  ﬂuctuations  development.  Age  of  onset  ≤50  years  was  associated
with  motor  ﬂuctuations  development.
Conclusion:  In conclusion,  our results  suggest  that  Parkinson’s  Disease  patients’  initial  characteristics,
such  as subtype  or age  of  onset,  are  independently  associated  with  the  development  of  motor  complica-
tions.
© 2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
en  acS.L.U.  This  is an op
ntroduction
Parkinson’s Disease (PD) is a neurodegenerative disorder
escribed in 1817 by James Parkinson.1 Since his publication, “An
ssay on Shaking Palsy”,1 there has been a crescent scientiﬁc inter-
st on this subject. According to the most accepted theory, it
as suggested that PD has a spreading character correlated with
eposition of abnormal aggregates which create a signiﬁcant loss
Abbreviations: AR, Akinesia/rigidity; CI, conﬁdence interval; DA, dopaminergic
gonists; DFS, dyskinesias-free survival; DK, dyskinesia; MC,  motor complications;
F,  motor ﬂuctuation; MFFS, motor ﬂuctuations-free survival; PD, Parkinson’s Dis-
ase; TD, tremor dominant.
∗ Corresponding author.
E-mail address: asrrafael@gmail.com (A.S. Rua Rafael).
http://dx.doi.org/10.1016/j.pbj.2016.08.001
444-8664/© 2016 PBJ-Associac¸a˜o Porto Biomedical/Porto Biomedical Society. Publishe
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).cess  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
of dopaminergic enervation in Substantia Nigra pars compacta.2
Motor symptoms begin when loss in dopamine uptake becomes
≥50%.3
In clinical practice, main symptoms are muscular rigidity, rest
tremor and/or postural instability.4 One of the most common and
simplest used scales to assess motor progression and severity of PD
is the Modiﬁed Hoehn and Yahr Scale (H&Y).5
As a deﬁnitive solution is yet to be found, treatment can be the
most challenging phase. General measures can reduce the impact
of motor symptoms, but not completely, and surgical treatments
are indicated in advanced disease6,7; differently, pharmacological
therapy is widely used.8 Many drug classes are available – such
as MAO-B inhibitors, dopaminergic agonists (DA) and anticholin-
ergic drugs – but the best drug in relieving motor symptoms is
levodopa.9,10 Associations with aromatic l-amino acid decarboxyl-
ase inhibitor and catechol-O-methyltransferase inhibitors are used
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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included in their therapy, did not develop MC,  until follow-up
ended.
General features from study population are described in Table 1.
Table 1
General features.
Feature n = 87
Gender
Male 44 (50.6%)
Female 43 (48.4%)
Age  (mean (SD)) 71.8 (9.7)
Age  at symptoms onset, (mean (SD)) 60.76 (10.0)
≤50 11 (12.6%)
51  and 60 35 (40.2%)
>60  41 (47.1%)
Time until diagnosis (mean (SD)) 1.6 (0.8)
Parkinson’s Disease Subtype
Tremor dominant 45 (51.7%)
Akinesia/rigidity 32 (36.8%)
Mixed 10 (11.5%)
1st  Drug
Dopaminergic agonist 38 (43.7%)
Levodopa 47 (54.0%)
Other 2 (2.3%)
H&Y at levodopa onset, (median (range)) 2 (1–4)A.S. Rua Rafael et al. / Port
o optimize drug action and reduce side effects like nausea and
omiting.11
With the risk of undertreatment, levodopa introduction is
ometimes delayed because of the most feared levodopa-induced
otor complications (MC): dyskinesia (DK) and motor ﬂuctuations
MF).12
MF  include “wearing-off” phenomena - symptoms re-
ppearance just before the next levodopa dose – and generally it is
he ﬁrst MC.  MF  also include “on-off” phenomena – sudden changes
etween normal and parkinsonic motor state; and “delayed on”
henomena – when symptoms relief takes longer.12,13
DK are deﬁned as involuntary movements, the most common
re chorea and dystonia, that can affect any body region, usually an
xtremity.12 This region can coincide with the ﬁrst one affected by
otor symptoms of PD.13 Initially they are peak-dose related, but
an also be dysphasic – according to levodopa blood levels rise and
all – or “off dyskinesias” – when these levels are low.13,14
Although less and later than in the past, nowadays a signiﬁ-
ant part of PD patients develop these MC:  9 or more years after
eginning levodopa, close to 90% of patients will develop DK and
0% MF.15 In Portugal, it was reported that patients with MF  have
 times more socio-economic costs than MF-free patients.16 Also,
uality of life is greatly impaired in PD patients with MC.  Their
obility, daily living activities or communication skills can be com-
romised, and stigmatization is frequent.17
MC  are important obstacles to the everyday life of PD patients. It
s vital not only to understand their etiology and pathophysiology,
ut also to understand what can be made to prevent them right
ince the ﬁrst medical approach.
Our objective was to identify which Parkinson’s Disease’s,
atient’s and therapeutics’ initial features are more associated with
yskinesias or motor ﬂuctuations development.
ethods
tudy design
This is an observational, analytical, non-interventional, non-
omparative, retrospective, longitudinal study. It took place in a
entral university hospital, Hospital São João, Porto, Portugal.
Source of information were clinical records of patients followed
n the hospital’s outpatient clinic by two movement disorders neu-
ologists (C.G. and M.J.R.) in periodic appointments.
The research protocol was certiﬁed by the ethical committee
f Faculty of Medicine of Porto University and by the ethical com-
ittee of Hospital São João, respecting the Declaration of Helsinki
rinciples.
atient selection
Patients were selected according to the following inclusion
riteria: appointments in Hospital São João outpatient’s clinic,
iagnosis of PD, and attendance of at least two appointments of
ovement disorder since 2012. In these appointments, the diag-
osis of PD is based on UK Parkinson’s Disease Society Brain Bank.4
Patients who had secondary causes of parkinsonism, uncertain
iagnosis, missing data about ﬁrst pharmacological therapy, lev-
dopa not included in therapy, follow-up time less than 3 years or
revious treatment with neurosurgical treatment, were excluded.
ata collectionEach patient’s entry date was the year of ﬁrst appointment and,
or all, follow-up ended in August 2014. No blinding procedures
ere needed.ed. J. 2016;1(4):136–141 137
To gather all the information, a database was created using
Microsoft Ofﬁce Excel 2007. The studied variables were: gender,
age at symptoms onset, time between symptoms onset and diag-
nosis, PD subtype at onset (tremor dominant (TD), Akinesia/rigidity
(AR) or mixed), H&Y class at levodopa onset, time between DA onset
and levodopa onset, initial drug (levodopa, DA or other), evolution
of ﬁrst year levodopa dose, presence of MF  and/or DK and time since
levodopa onset until the occurrence of MF  and/or DK. The last one
was used as our dependent variable.
Statistical analysis
Statistical analysis was  performed with IBM SPSS Statistics 22
according to a survival model. Dyskinesias-free survival (DFS) and
Motor ﬂuctuations-free survival (MFFS) were deﬁned as the time
from levodopa onset until the occurrence of DK or MF, respec-
tively, or the most recent follow-up. Patients without DK or MF
were censored in the last follow-up date. Continuous variables were
expressed as the median, percentile 25 (p25) and percentile 75
(p75). For further data analyses, these variables were categorized.
A Kaplan–Meier estimate was used to calculate the median sur-
vival time and survival rate free of each MC. Outcome predictors
were evaluated using univariate and multivariate Cox proportional
regression analysis. Multivariate analysis was  used to account for
confounding variables; the ones included were those with a signif-
icance of p < 0.20 in univariate analysis. Results were expressed as
hazard ratio (HR) with 95% conﬁdence interval (CI). A p-value <0.05
was used as criteria for statistical signiﬁcance in the multivariate
model.
Results
Baseline features
After applying inclusion and exclusion criteria, 87 patients were
included in this study. Patients excluded for not having levodopaMotor Complications 45 (51.7%)
Dyskinesias 31 (35.6%)
Motor Fluctuations 28 (32.2%)
SD, standard deviation; H&Y, Hoehn and Yahr class.
138 A.S. Rua Rafael et al. / Porto Biomed. J. 2016;1(4):136–141
1.0
0.8
n=87; 56 free of DK
survival rates:
4-year rate 88.0%
8-year rate 64.1%
0.6
0.4
0.2
0.0
0 4 8
Cu
m
u
la
tiv
e
 s
u
rv
iva
l
Survival function Censored
12
Duration of levodopa therapy (years)
16 20
F
o
P
p
f
p
6
w
D
(
p
o
f
t
s
P
p
f
p
6
f
o
t
c
(
s
s
5
Table 2
Factors associated with DFS: unadjusted and adjusted HR.
Characteristic Unadjusted Adjusted
HR (95% CI) p-Value HR (95% CI) p-Value
Gender
Male 1 (ref)
Female 1.3 (0.6; 2.6) 0.540
Age at symptoms onset
≤50 2.7 (0.9; 7.7) 0.066 4.2 (0.9; 19.0) 0.061
51  and 60 1.0 (0.4; 2.1) 0.936 0.8 (0.3; 2.0) 0.572
>60  1 (ref) 1 (ref)
Time until diagnosis
1  1 (ref)
2  1.0 (0.4; 2.4) 0.962
3 1.0 (0.4; 2.8) 0.936
Parkinson’s Disease subtype
Tremor dominant 1 (ref) 1 (ref)
Akinesia/rigidity 1.8 (0.9; 3.7) 0.126 3.0 (1.2; 7.3) 0.018
Mixed 1.1 (0.2; 4.7) 0.937 0.3 (0.1; 2.2) 0.264
Hoehn and Yahr class at levodopa onset
1 1 (ref)
1.5 0.9 (0.3; 2.4) 0.836
2  1.0 (0.4; 2.6) 0.993
2.5 0.8 (0.2; 2.5) 0.688
Time between DA onset and levodopa onset
0a 1 (ref) 1 (ref)
1 2.0 (0.7; 6.1) 0.187 2.5 (0.8; 7.8) 0.123
2  1.1 (0.4; 2.9) 0.842 0.9 (0.3; 3.1) 0.927
Initial drug
Levodopa 1 (ref)
DA 1.2 (0.6; 2.6) 0.628
1st year dose
Equal or lower 1 (ref)
≤150 0.6 (0.2; 2.1) 0.457
150 and 250 0.4 (0.1; 1.9) 0.263
250 1.8 (0.7; 4.8) 0.243
Motor ﬂuctuations presence
No 1 (ref)
Yes 0.9 (0.4; 2.0) 0.859ig. 1. Kaplan–Meier estimate for Parkinson’s Disease patients’ probable time free
f  dyskinesias, since levodopa onset.
redictors of DFS
After a median follow-up of 6 years (range 1–17), 56 (64.4%)
atients did not present DK at the time of this report. The median
ree-survival rate for DK was 10 years.
Kaplan–Meier curve about DFS estimate shows that, of all
atients, 88.0% did not present DK on the 4th year and neither did
4.1% on the 8th year (Fig. 1).
As presented in Table 2, multivariate Cox regression analysis
as performed on the age group, subtype of PD and time between
A onset and levodopa onset, as they were statistically signiﬁcant
p < 0.20) in the univariate analysis.
Subtype was an independent predictor for onset of DK in PD
atients. AR subtype had a statistically signiﬁcant higher risk for DK
nset when compared to TD subtype, after adjusting for all other
actors (HR = 3.0; 95% CI: 1.2; 7.3). On the other hand, age of onset,
ime between DA and levodopa onset, did not remained statistically
igniﬁcant.
redictors of MFFS
After a median follow-up of 5 years (range 1–16), 59 (67.8%)
atients did not present MF  at the time of this report. The median
ree-survival rate for MF  was 15 years.
Kaplan–Meier curve about MFFS estimate shows that, of all
atients, 84.2% did not present MF  on the 4th year and neither did
4.4% on the 8th year (Fig. 2).
As presented in Table 3, multivariate Cox regression was per-
ormed on the age group, subtype of PD and H&Y class at levodopa
nset, as they were found to be statistically signiﬁcant (p < 0.20) in
he univariate analysis.
After multivariate analysis, the age group ≤50 years was  asso-
iated with worse free survival, presenting an increased HR of MF
HR = 3.6; 95% CI: 1.3; 10.0). Also, AR subtype had a statistically
igniﬁcant higher risk of MF  development when compared to TD
ubtype, after adjusting for all other factors (HR = 2.4; 95% CI: 1.0;
.7). H&Y class did not remain statistically signiﬁcant.DKS, Dyskinesias-free survival; HR, hazard ratio; CI, conﬁdence interval; DA,
dopaminergic agonists.
a Never had or started DA after levodopa.
Discussion
Several observational retrospective studies were conducted
aiming to ﬁnd risk factors associated with the development of lev-
odopa induced MC.18–20
In the present study, DK development was  correlated with
AR subtype at the onset of PD symptoms. AR subtype was  also
related with a higher risk of developing MF.  Another factor found
to be independently related with MF  was age at symptoms onset:
patients with ≤50 years old were more prone to develop MF.
Comparing present results to previous retrospective studies,
similar rates of MC  were reported. In the present sample, 51.7% of
the patients developed MC,  comparing to 62% in another study.21
Regarding studied MC,  35.6% patients developed DK and 32.2% MF;
in previous studies DK rates ranged from 28% to 30.1% and MF  rates
from 40% to 46.3%.19,20
Concerning Kaplan–Meier analysis, 12% of patients presented
DK after 4 years of levodopa therapy and 35.9% after 8 years. MF
were present in 15.8% of patients after 4 years and in 35.6% after
8 years. In a cross-sectional study, DK were present in 13% of the
patients with 5 or less years of treatment duration, and in 36% after
6 to 9 years. MF  were present in 21% of patients with 5 or less years
and in 56% after 6–9 years.20 Except for MF  at 8-years, similar rates
were described, showing that our population’s MC  characteristics
can be comparable to others.
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Table 3
Factors associated with MFFS: unadjusted and adjusted HR.
Characteristic Unadjusted Adjusted
HR (95% CI) p-Value HR (95% CI) p-Value
Gender
Male 1 (ref)
Female 1 (0.4;2.1) 0.914
Age of symptoms onset
≤50 3.6 (1.3;10.0) 0.013 3.6 (1.1; 11.8) 0.033
51  and 60 0.7 (0.3; 1.7) 0.465 0.7 (0.3; 1.7) 0.405
>60  1 (ref) 1 (ref)
Time until diagnosis
1 1 (ref)
2  0.9 (0.4; 2.3) 0.990
3  1.0 (0.4; 2.8) 1.005
Parkinson’s Disease subtype
Tremor dominant 1 (ref) 1 (ref)
Akinesia/rigidity 2.4 (1.1; 5.4) 0.034 2.4 (1.0; 5.7) 0.039
Mixed 3.4 (1.0; 11.1) 0.046 1.8 (0.4; 7.1) 0.429
Hoehn and Yahr class at levodopa onset
1 1 (ref) 1 (ref)
1.5 0.5 (0.2; 1.4) 0.162 0.5 (0.2; 1.5) 0.203
2  0.9 (0.3; 2.3) 0.809 0.7 (0.2; 1.8) 0.426
2.5  0.7 (0.2; 2.3) 0.578 0.6 (0.2: 1.9) 0.367
Time between DA onset and levodopa onset
0a 1 (ref)
1  1.5 (0.5; 4.8) 0.481
2  0.9 (0.3; 2.5) 0.797
Initial drug
Levodopa 1 (ref)
DA 1.4 (0.6; 3.0) 0.453
1st year dose
Equal or lower 1 (ref)
≤150 1.6 (0.6; 4.2) 0.320
150 and 250 1.1 (0.3; 3.7) 0.929
250 1.0 (0.3; 3.5) 0.983
Dyskinesias presence
No 1 (ref)
Yes 1.2 (0.5; 2.6) 0.657
MFFS, motor ﬂuctuations-free survival; HR, hazard ratio; CI, conﬁdence interval; DA,
levodopa is the fact that it does not cause cognitive impairment as
DA does, so it can be used in older patients.12f  motor ﬂuctuations, since levodopa onset.
Previous retrospective studies reported that initial TD subtype
as associated with lower probability of DK, independently of other
isk factors.22–24 A clinical review concluded that recognition of
he phenotype is important for PD managing since patients with
D subtype are associated with a more benign disease course and
ewer MF.25 A possible explanation for these results was  suggested
y imaging studies that correlated AR subtype with a higher clinical
rogression and dopaminergic loss in putamen.26 Although a cross-
ectional study reported that AR subtype was more common in
atients with MF  than with DK,20 our study found AR subtype to be
ndependently correlated in MF  and DK development.
Average age at symptoms onset was 60.76 (Standard Deviation
SD) 10.0) years, comparable with mean age in other studies: 63.8
SD 8.5) and 64.5 (SD 7.3) years.20,27 Younger ages at PD symptoms
nset were demonstrated to inﬂuence MF  development in a pre-
ious cross-sectional, retrospective study.27 No relation with DK
ccurrence was found in the referred studies.20,27 Similarly, in other
tudies, including a survival community-based cohort, younger age
as not found to be an independent risk factor for DK.18,28 Analo-
ous results were obtained in our study: younger age of onset was
ssociated with development of MF,  but not DK. Although in some
tudies DK were inﬂuenced by age of symptoms onset,19,24 it has
een suggested that MF  and DK have a different pathophysiology.29
Some studies reported that DK was more common in
emales.18,19 Though, in previous studies and in ours, gender does
ot appear to inﬂuence development of MC.20,24,27
Time between symptoms onset and diagnosis did not appear
o be associated with development of DK or MF. This variable was
ot studied in others studies of our knowledge. Given that most
atients start treatment at the moment of diagnosis, there are sim-
lar results in other studies concerning levodopa onset.19,20
H&Y class at levodopa onset had a median of 2 (range 1–4),
nd no relationship was found concerning MC development. In a
revious study relating H&Y class and MC  onset, it was  described
hat earlier MC  occurred when levodopa was introduced in H&Ydopaminergic agonist.
a Never had or started DA after levodopa.
class 3. Yet, in the mentioned study, patients were drug-free before
levodopa onset, unlike our study.30
In patients who  started DA before levodopa, time between
them was  related neither with MF  nor DK. Concerning ﬁrst phar-
macological choice, other studies support our ﬁnding that there
is no association between patients who start with DA or with
levodopa.20 Although some clinical-trials found it statistically
signiﬁcant,21 a recent clinic-pathological study concluded that
delaying levodopa onset in order to avoid levodopa is unnecessary;
MC were associated with disease progression, not levodopa.31 Also,
a placebo-controlled trial concluded that, in a clinical perspective,
levodopa therapy, in early-onset PD patients, does not accelerate PD
progression.32 It is interesting to note that some studies, trying to
ﬁnd differences between starting medical therapy with a speciﬁc
DA or with levodopa, suggest that development of MC  is similar
in both groups at long term.33,34 Mortality in patients who  start
levodopa in early stages of PD symptoms onset was  found to be
similar to those who  start it in later stages.35 It was  suggested that
levodopa therapy would reduce mortality, possibly by improving
motor symptoms in later PD stages.36 A major advantage on usingWe tried to evaluate if 1st year dose evolution inﬂuenced the
development of MC  but there were no statistically signiﬁcant
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esults. A hospital-based study concluded that initial levodopa dose
as higher in patients with MC.19 Information in other studies
bout levodopa dose evolution in the 1st year was not found.
Presence of MF  did not change DK appearing and neither the
everse. In other studies, the majority of patients with MF  devel-
ped DK or there was a relationship between them.19,21 It was
uggested that DK would predict MF  appearing37 but that is yet
o be determined.
Measures can be taken to manage MC.  A huge matter of debate
s whether the use of DA has a protective effect on MC  or not.
tudies suggest that the delay on MC  when using DA as ﬁrst med-
cal approach is due to the delay in levodopa introduction and not
 neuroprotective process.34,38 However, after longer follow-ups,
here are contradictory ﬁndings about the existence of a “catch-up”
echanism or a real MC delay.33,34,39 It seems to be a consensus that
sing the lowest levodopa dose necessary for good clinical control
inimizes both DK and MF.40
These comparisons are restricted because of the statistical
ethod used in the present study: we are not aware of other studies
ith the similar analysis method and objective. A survival analy-
is model was considered the best option since participants in our
tudy had a different follow-up time and at the end of follow-up not
ll participants developed MC;  it has the advantage of retrieving
nformation about those patients too.41 Different results between
tudies may  also occur because of different treatment regiments or
ifferent population characteristics.
Although ideal to chronic diseases like PD, the present study
as some limitations related to its retrospective observational
ature. A major limitation was data collection: many patients
ere excluded by lack of data and, although trustable, the only
nformation we had access was the written one. Due to unde-
ned guidelines, confounding/treatment-by-indication bias may
e present, for example the tendency to start with DA, not lev-
dopa, in younger patients, which is also a variable related with
he outcome. We tried to control confounding factors by using
ultivariable analysis. Other disadvantage is the absence of a ran-
omized sample which would confer more external validity to the
tudy. As there was no direct control, we also have to consider the
ossibility of low adherence to medication in these patients.42
Regarding advantages when comparing to other studies,
ecording-bias is not in question, making data more accurate.
lso, patients’ information was written in clinical records by 2
ovement disorders neurologists and therapeutic adjustments in
rugs were made only by them. Besides, since our study is a non-
nterventional observational study, a more natural and realistic
pproach to day-to-day PD and its’ MC  was made. Finally, follow-up
ength (16–17 years) allows for more precise information.
In conclusion, our results suggest that patients’ disease initial
haracteristics, such as subtype or age of PD onset, are indepen-
ently associated with the development of MC,  rather than the ﬁrst
rug used in therapy.
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